Predicting the Risk of Venous Thromboembolism in Patients Hospitalized With Heart Failure
Why the study?
Does heart failure severity predict the risk of venous thromboembolism in hospitalized patients?
Population
2,593 hospitalized patients diagnosed with heart failure from the MAGELLAN trial
Comparison
Extended-duration rivaroxaban vs Standard-duration enoxaparin followed by placebo
Design
Cohort, Randomized, parallel group (in the parent trial)
Follow-up
Up to Day 35
Authors
Discussion
Loading...
Member takes
Overview
HF severity was associated with higher VTE risk in hospitalized patients; hypothesis-generating for severity-stratified prophylaxis trials.
Structured PICO
Does heart failure severity predict the risk of venous thromboembolism in hospitalized patients?
P
Population
2,593 hospitalized patients diagnosed with heart failure (NYHA class III or IV at admission) from the MAGELLAN trial
I
Intervention
Extended-duration rivaroxaban
C
Comparator
Standard-duration enoxaparin followed by placebo
O
Outcome
Incidence of venous thromboembolism (VTE) up to Day 10 and Day 35hard clinical
Higher NT-proBNP and D-dimer levels identify hospitalized heart failure patients at increased short- and mid-term risk for venous thromboembolism.
Cite This Study
Mebazaa et al. (2014) studied this question.